Retinalamin
A bovine-retina-derived Khavinson polypeptide bioregulator studied for neuroprotective and anti-aging effects on photoreceptors and retinal ganglion cells.
Retinalamin is a polypeptide bioregulator preparation derived from retinal tissue, classified as a Khavinson-class agent investigated for neuroprotective and anti-aging effects in photoreceptors and retinal ganglion cells. It is proposed to support visual function by normalizing retinal pigment epithelial and photoreceptor cell function, reducing oxidative damage, and modulating gene expression in aging or degenerating retinal tissue. It has no FDA approval and is used clinically in Russia and Eastern Europe for degenerative retinal conditions, with an evidence base drawn largely from Russian-origin preclinical and observational studies.
Class
Polypeptide tissue bioregulator (Khavinson class, bovine retina-derived)
Half-life
Unknown
Routes
Parabulbar injection, Intramuscular
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Retinal cell protection
Proposed to normalize retinal pigment epithelial and photoreceptor cell function and reduce oxidative damage in retinal tissue, protecting cells under degenerative or age-related stress. Evidence is emerging and drawn from class-level mechanistic and Russian-origin studies.
Visual function restoration
Investigated for supporting and restoring visual function in aging retinal tissue by modulating cellular homeostasis in photoreceptors and retinal ganglion cells.
Macular degeneration support
Studied as supportive care in age-related retinal degeneration, one of the conditions for which it is used clinically in Russia and Eastern Europe.
Anti-aging effects in the eye
Proposed to exert anti-aging effects on retinal tissue by modulating transcriptional activity in retinal pigment epithelium and photoreceptor cells, consistent with the Khavinson bioregulator framework of tissue-specific gene-expression regulation.
Mechanism
How it works
Retinalamin is a polypeptide bioregulator preparation derived from bovine retinal tissue. Like other Khavinson bioregulator preparations, it is proposed to exert tissue-specific regulatory effects through the intracellular transport of ultrashort active peptide components via amino acid carrier mechanisms, modulating transcriptional activity in retinal pigment epithelium and photoreceptor cells under degenerative or age-related stress conditions.
At the class level, published research on Khavinson-class ultrashort peptides has characterized their cellular uptake via POT and LAT transporter systems, demonstrating nuclear translocation and chromatin binding. This provides the mechanistic framework within which retinalamin is proposed to regulate gene expression and support cellular homeostasis in aging retinal tissue.
Functionally, retinalamin is described as normalizing retinal pigment epithelial and photoreceptor cell function and reducing oxidative damage in retinal tissue, which is the proposed basis for its neuroprotective and visual-function effects.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Clinical (reference)
- Dose
- Not specified in available sources
- Frequency
- Not specified
- Timing
- Not specified
- Duration
- Not specified
- Route
- Parabulbar injection or intramuscular
Available source material documents administration routes (parabulbar injection and intramuscular) but does not provide specific dose amounts, frequency, or course length. In its Russian clinical use it is administered by a qualified professional.
- No specific dosing numbers, reconstitution guidance, or course length are provided in the available source material.
- Documented administration routes are parabulbar (peri-ocular) injection and intramuscular injection.
- Ask any provider for a Certificate of Analysis (COA) and proper reconstitution and handling guidance before use.
Evidence
Research & clinical studies (2)
Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium
Documents the cellular uptake of short regulatory peptides including retinalamin via POT and LAT transporter systems, showing nuclear translocation and chromatin binding relevant to retinalamin's transcriptional regulatory function in retinal cells.
PMID 35887081Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies
Examines the bioavailability and biological activities of short peptides including retinalamin and related retinal peptide regulators, providing mechanistic context for their effects on retinal tissue protection and age-related degenerative changes.
PMID 35457077Safety
Side effects & considerations
Contraindications & cautions
- Bovine protein allergy
Retinalamin is generally considered lower risk in research contexts. Because it is derived from bovine retinal tissue, individuals with bovine protein allergy should avoid it. Individual response varies; review all considerations and consult a qualified professional before use.
FAQ
Retinalamin — common questions
What is Retinalamin?
Retinalamin is a polypeptide bioregulator preparation derived from retinal tissue, classified as a Khavinson-class agent investigated for neuroprotective and anti-aging effects in photoreceptors and retinal ganglion cells. It is proposed to support visual function by modulating gene expression and cellular homeostasis in aging retinal tissue.
What is Retinalamin primarily studied for?
Retinal cell protection, visual function restoration, macular degeneration support, and anti-aging effects in the eyes.
How is Retinalamin administered?
Documented administration routes are parabulbar (peri-ocular) injection and intramuscular injection. Specific dosing details are not provided in the available source material.
What are the side effects of Retinalamin?
It is considered lower risk in research contexts. The main reported contraindication is bovine protein allergy, since the preparation is derived from bovine retinal tissue. Consult a qualified healthcare professional before use.
Is Retinalamin FDA-approved?
No. Retinalamin is not FDA-evaluated. It is used as a clinical preparation in Russia and Eastern Europe for degenerative retinal conditions and is available in the US only as a research chemical.
What does the research show about Retinalamin?
The cited evidence is emerging and drawn from two reviews of Khavinson-class short peptides. These document cellular uptake via POT and LAT transporter systems, nuclear translocation, and chromatin binding relevant to retinalamin's proposed transcriptional regulatory function in retinal tissue. Russian-origin preclinical and observational studies have not been independently replicated in Western-indexed clinical literature.
